These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 30229376)

  • 61. Similarities and differences between stakeholders' opinions on using Health Technology Assessment (HTA) information across five European countries: results from the EQUIPT survey.
    Vokó Z; Cheung KL; Józwiak-Hagymásy J; Wolfenstetter S; Jones T; Muñoz C; Evers SM; Hiligsmann M; de Vries H; Pokhrel S;
    Health Res Policy Syst; 2016 May; 14(1):38. PubMed ID: 27230485
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Health Technology Assessment and Its Use in Drug Policies: Singapore.
    Pearce F; Lin L; Teo E; Ng K; Khoo D
    Value Health Reg Issues; 2019 May; 18():176-183. PubMed ID: 29954696
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Linking the Regulatory and Reimbursement Processes for Medical Devices: The Need for Integrated Assessments.
    Ciani O; Wilcher B; van Giessen A; Taylor RS
    Health Econ; 2017 Feb; 26 Suppl 1():13-29. PubMed ID: 28139087
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Best-worst scaling to assess the most important barriers and facilitators for the use of health technology assessment in Austria.
    Feig C; Cheung KL; Hiligsmann M; Evers SMAA; Simon J; Mayer S
    Expert Rev Pharmacoecon Outcomes Res; 2018 Apr; 18(2):223-232. PubMed ID: 28862060
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Addressing challenges for sustainable healthcare in Central and Eastern Europe.
    Godman B; Novakovic T; Tesic D; Oortwijn W; Martin AP; Parker M; Haycox A
    Expert Rev Pharmacoecon Outcomes Res; 2016 Dec; 16(6):685-687. PubMed ID: 26966924
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force.
    Sullivan SD; Mauskopf JA; Augustovski F; Jaime Caro J; Lee KM; Minchin M; Orlewska E; Penna P; Rodriguez Barrios JM; Shau WY
    Value Health; 2014; 17(1):5-14. PubMed ID: 24438712
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Qualitative comparative analysis of health economic evaluation guidelines for health technology assessment in European countries.
    Zisis K; Naoum P; Athanasakis K
    Int J Technol Assess Health Care; 2020 Dec; 37():e2. PubMed ID: 33298238
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Financing and Reimbursement of Approved Advanced Therapies in Several European Countries.
    Iglesias-López C; Agustí A; Vallano A; Obach M
    Value Health; 2023 Jun; 26(6):841-853. PubMed ID: 36646280
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Early assessment of medical technologies to inform product development and market access: a review of methods and applications.
    Ijzerman MJ; Steuten LM
    Appl Health Econ Health Policy; 2011 Sep; 9(5):331-47. PubMed ID: 21875163
    [TBL] [Abstract][Full Text] [Related]  

  • 70. A Health Economics Approach to US Value Assessment Frameworks-Introduction: An ISPOR Special Task Force Report [1].
    Neumann PJ; Willke RJ; Garrison LP
    Value Health; 2018 Feb; 21(2):119-123. PubMed ID: 29477388
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The value of innovation in decision-making in health care in Central Eastern Europe - The Sixth International Conference, 2 June 2017, Belgrade, Serbia.
    Novakovic T; Martin AP; Parker M; Ferrario A; Vukovic S; Łanda K; Duba J; Dankó D; Kotsopoulos N; Godman B; Ristic J; Stefanovic D; Tesic D
    Expert Rev Pharmacoecon Outcomes Res; 2017 Dec; 17(6):519-521. PubMed ID: 28946800
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Value Assessment Frameworks for HTA Agencies: The Organization of Evidence-Informed Deliberative Processes.
    Baltussen R; Jansen MPM; Bijlmakers L; Grutters J; Kluytmans A; Reuzel RP; Tummers M; der Wilt GJV
    Value Health; 2017 Feb; 20(2):256-260. PubMed ID: 28237205
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Development of archetypes for non-ranking classification and comparison of European National Health Technology Assessment systems.
    Allen N; Pichler F; Wang T; Patel S; Salek S
    Health Policy; 2013 Dec; 113(3):305-12. PubMed ID: 24176288
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Health technology assessment in Saudi Arabia.
    Al-Aqeel S
    Expert Rev Pharmacoecon Outcomes Res; 2018 Aug; 18(4):393-402. PubMed ID: 29733227
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Integrating health technology assessment requirements in the clinical development of medicines: the experience from NICE scientific advice.
    Maignen F; Osipenko L; Pinilla-Dominguez P; Crowe E
    Eur J Clin Pharmacol; 2017 Mar; 73(3):297-305. PubMed ID: 27942759
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Oncology from an HTA and Health Economic Perspective.
    Francois C; Zhou J; Pochopien M; Achour L; Toumi M
    Recent Results Cancer Res; 2019; 213():25-38. PubMed ID: 30543005
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Regulation of advanced therapy medicinal products in Europe and the role of academia.
    Pearce KF; Hildebrandt M; Greinix H; Scheding S; Koehl U; Worel N; Apperley J; Edinger M; Hauser A; Mischak-Weissinger E; Dickinson AM; Lowdell MW
    Cytotherapy; 2014 Mar; 16(3):289-97. PubMed ID: 24113428
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Is there an alternative to quality-adjusted life years for supporting healthcare decision making?
    Beresniak A; Dupont D
    Expert Rev Pharmacoecon Outcomes Res; 2016 Jun; 16(3):351-7. PubMed ID: 27139424
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Patient access to and ethical considerations of the application of the European Union hospital exemption rule for advanced therapy medicinal products.
    Cuende N; Ciccocioppo R; Forte M; Galipeau J; Ikonomou L; Levine BL; Srivastava A; Zettler PJ
    Cytotherapy; 2022 Jul; 24(7):686-690. PubMed ID: 35545453
    [TBL] [Abstract][Full Text] [Related]  

  • 80. EVALUATION OF THE HTA CORE MODEL FOR NATIONAL HEALTH TECHNOLOGY ASSESSMENT REPORTS: COMPARATIVE STUDY AND EXPERIENCES FROM EUROPEAN COUNTRIES.
    Kõrge K; Berndt N; Hohmann J; Romano F; Hiligsmann M
    Int J Technol Assess Health Care; 2017 Jan; 33(6):644-653. PubMed ID: 29157316
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.